Test Price
2,800 AED✅ Home Collection Available
ZSWIM6 Gene Acromelic Frontonasal Dysostosis Genetic Test in UAE | 2,800 AED | 2026 DHA Guidelines
تحليل جين ZSWIM6 لخلل التعظم الجبهي الأنفي الطرفي في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
الفحص الجيني المتقدم لجين ZSWIM6 لتشخيص خلل التعظم الجبهي الأنفي الطرفي باستخدام تقنية التسلسل الجيني من الجيل التالي (NGS) في دولة الإمارات العربية المتحدة، بضمان دقة تشخيصية تصل إلى 99.9% وامتثال كامل للقوانين الاتحادية.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed Physician.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Overview
This advanced genetic test screens the ZSWIM6 gene for pathogenic variants responsible for acromelic frontonasal dysostosis (AFND), a rare dysmorphology syndrome characterized by craniofacial and limb anomalies, using high‑throughput Next Generation Sequencing (NGS). يقوم هذا الفحص بتحليل جين ZSWIM6 للكشف عن الطفرات المسببة لخلل التعظم الجبهي الأنفي الطرفي باستخدام التسلسل الجيني المتقدم، مما يتيح تشخيصًا جزيئيًا دقيقًا.
| Feature | Our Test (NGS) | Alternative (Sanger Sequencing) |
|---|---|---|
| Detection Scope | Full gene coverage – all exons, splice sites, and regulatory regions | Limited to pre‑selected exons; may miss deep intronic or regulatory variants |
| Sensitivity | >99.9% analytical sensitivity for single nucleotide variants and small indels | ~98% for targeted regions; lower for uncommon mutations |
| Turnaround Time | 3–4 weeks with integrated bioinformatics pipeline | 4–6 weeks; often requires sequential testing |
| Compliance | DHA 2026 Guidelines, UAE Federal Decree-Law No. 41 of 2024 | Varies by provider |
Physician Insight & Safety Protocol
Note from Dr. PRABHAKAR REDDY (DHA: 61713011): “I understand the anxiety that comes with a child’s developmental concerns. This test provides a definitive molecular diagnosis for acromelic frontonasal dysostosis, guiding clinical management and family planning. However, results must always be correlated with comprehensive clinical evaluation and genetic counselling.”
⚠ Important Medication Warning:
Do not discontinue or modify any prescribed medication without consulting your doctor. The genetic test does not replace ongoing clinical treatment.
Exclusion Criteria & ER Red Flags
- Exclusion: Severe coagulopathy precluding safe blood draw; neonates less than 48 hours old for FTA card collection; inability of guardian to provide informed consent (strict adherence to UAE CDS Law 2026 for minors).
- Emergency Red Flags – seek immediate medical attention if experiencing: Sudden severe craniofacial pain, rapid neurological deterioration, respiratory distress, signs of increased intracranial pressure (persistent vomiting, lethargy, bulging fontanelle in infants). These symptoms are unrelated to the test procedure but require urgent care.
Patient FAQ & Clinical Guidance
Q: What is the purpose of the ZSWIM6 gene test? (ما هو الهدف من فحص جين ZSWIM6؟)
This NGS test identifies pathogenic ZSWIM6 mutations causing acromelic frontonasal dysostosis for accurate molecular diagnosis. It enables clinicians to confirm the condition, differentiate it from other craniofacial syndromes, and develop a personalized multispecialty management plan including paediatric surgery, endocrinology, and developmental follow‑up.
Q: How is the test performed and what sample is required? (كيف يتم الفحص وما هي العينة المطلوبة؟)
Blood, DNA, or an FTA card drop sample is collected by our home phlebotomy team. A small volume of whole blood, previously extracted DNA, or a single drop of blood dried on an FTA card is obtained through a painless procedure by a certified phlebotomist at your home (8 AM – 11 PM). The sample is transported in temperature‑controlled containers to our ISO‑accredited laboratory.
Q: Is genetic counselling required before the test? (هل يجب تقديم استشارة وراثية قبل الفحص؟)
A pre‑ genetic counselling session is required to review family history and explain potential outcomes. Our board‑certified genetic counsellors will draw a detailed pedigree chart, discuss the inheritance pattern (autosomal dominant), and outline the possible results – positive, negative, or variant of uncertain significance. This session is mandatory under UAE Federal Decree‑Law No. 41 of 2024 and ensures informed consent.
UAE Regulatory Compliance
امتثال تام للقانون الاتحادي رقم 41 لسنة 2024 بشأن الفحوصات الجينية (المادة 87) وقانون حماية بيانات المرضى (PDPL)، مع الالتزام بقانون سلامة الطفل (CDS) لعام 2026 فيما يخص القُصّر.
This service fully complies with Federal Decree‑Law No. 41 of 2024 (Art. 87) governing genetic testing, the UAE Child Digital Safety (CDS) Law 2026 for minors, and the UAE PDPL for data privacy. Facility License: 9834453. ISO 9001:2015 Certified (INT/EGQ/2509DA/3139).
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians